-
CTN-0138: Adaptation, implementation, and cluster randomized trial of a community pharmacy-based prescription drug monitoring program opioid risk assessment tool — A protocol paper.
Cochran GT, Brown JL Yu Z, Gordon AJ, Frede S, Hardy C, Castora-Binkley M, Homsted F, Marsch LA, Holtyn AF, Winhusen TJ. CTN-0138: Adaptation, implementation, and cluster randomized trial of a community pharmacy-based prescription drug monitoring program opioid risk assessment tool -- A protocol paper. Addiction Science & Clinical Practice 2024;19:82.
-
Randomized pilot of a clinical decision support tool to increase suicide screening for at-risk primary care patients with opioid use disorder.
Rossom RC, Crain AL, Bart GB, Boggs JM, O'Connor PJ, Borgert-Spaniol C, Kane S, Hooker SA. Randomized pilot of a clinical decision support tool to increase suicide screening for at-risk primary care patients with opioid use disorder. American Journal of Preventive Medicine Focus 2024;3(6):100280.
-
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes.
Bunting AM, Krawczyk N, Choo T, Pavlicova M, McNeely J, Tofighi B, Rotrosen J, Nunes EV, Lee JD. Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes. Journal of Substance Abuse Treatment 2022;143:108830.
-
Variation in opioid agonist dosing in clinical trials by race and ethnicity.
Ross RK, Inose S, Shulman M. Variation in opioid agonist dosing in clinical trials by race and ethnicity. JAMA Network Open 2024;7(10):e2436612.
-
Changes in prenatal cannabis use among pregnant individuals from 2012 to 2022.
Young-Wolff KC, Chi FW, Lapham GT, Alexeeff SE, Does MB, Ansley D, Campbell CI. Changes in prenatal cannabis use among pregnant individuals from 2012 to 2022. Obstetrics & Gynecology 2024;144(4):e101-e104.
-
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals.
Shearer R, Hagedorn H, Englander H, Siegler T, Kibben R, Fawale A, Patten A, Fitzpatrick A, Laes J, Fernando J, Appleton N, Oot E, Titus H, Krawczyk N, Weinstein Z, McNeely J, Baukol P, Ghitza U, Gustafson D, Bart G, Bazzi A. Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals. Journal of Substance Use and Addiction Treatment 2024;167:209520.
-
Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a multisite, randomized controlled trial conducted within the National Institute on Drug Abuse Clinical Trials Network.
Papa C, McClure EA, McCauley J, Haynes LF, Matheson T, Jones R, Jennings L, Lawdahl T, Ward R, Brady KT, Barth KS. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a multisite, randomized controlled trial conducted within the National Institute on Drug Abuse Clinical Trials Network. JMIR Research Protocols 2024;13:e60277.
-
A scoping review of social determinants of health’s impact on substance use disorders over the life course.
Lin C, Cousins SJ, Zhu Y, Clingan SE, Mooney LJ, Kan E, Wu F, Hser Y. A scoping review of social determinants of health's impact on substance use disorders over the life course. Journal of Substance Use & Addiction Treatment 2024;166:209484.
-
Machine learning-driven analysis of individualized treatment effects comparing buprenorphine and naltrexone in opioid use disorder relapse prevention.
Afshar M, Graham Linck EJ, Spicer AB, Rotrosen J, Salisbuy-Afshar EM, Sinha P, Semler MW, Churpek MW. Machine learning-driven analysis of individualized treatment effects comparing buprenorphine and naltrexone in opioid use disorder relapse prevention. Journal of Addiction Medicine 2024;18(5):511-519
-
Learning optimal dynamic treatment regimes from longitudinal data.
Williams NT, Hoffman KL, Diaz I, Rudolph KE. Learning optimal dynamic treatment regimes from longitudinal data. American Journal of Epidemiology 2024;193(12):1768-1775.